Breaking News Instant updates and real-time market news.

ARGX

Argenx

$115.07

2.25 (1.99%)

11:25
02/13/19
02/13
11:25
02/13/19
11:25

Argenx management to meet with Wolfe Research

Group Luncheon Meeting with CEO Van Hauwermeiren and COO Wood in New York on February 13 at 12 pm hosted by Wolfe Research.

  • 13

    Feb

ARGX Argenx
$115.07

2.25 (1.99%)

02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
01/08/19
PIPR
01/08/19
NO CHANGE
PIPR
Piper Jaffray believes Argenx's lead drug efgartigimod is 'best-in-class'
Piper Jaffray analyst Edward Tenthoff continues to believe Argenx's lead drug efgartigimod is a "best-in-class anti-FcRn antibody with a biological mechanism amenable to treating several autoimmune diseases characterized by upregulation of IgG." Further, the analyst is looking forward to the May 16 R&D Day to "highlight Argenx's exceptional drug discovery capabilities with introduction of ARGX-117 and ARGX-118." Tenthoff reiterated an Overweight rating and $161 price target on Argenx shares.
01/04/19
MSCO
01/04/19
INITIATION
Target $140
MSCO
Overweight
Argenx initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison initiated Argenx with an Overweight rating and $140 price target, stating that he sees ARGX-113 as a "best-in-class assets" in the anti-FcRn antibody space given its safety, affinity and durability. He sees the key indications of generalized myasthenia gravis, primary immune thrombocytopenia and pemphigus vulgaris providing a greater than $5B market opportunity, adding that he estimates Argenx could capture over $1B in sales by 2026.
12/17/18
GSCO
12/17/18
NO CHANGE
GSCO
Goldman starts Argenx at Conviction Buy, upgrades Orchard to Buy
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Argenx (ARGX) with a Buy rating and $154 price target while adding the shares to his firm's Pan-Europe Conviction List. The company has "unique" antibody technology and a "promising" Phase 3 asset in efgartigimod for the treatment of severe autoimmune disorders, Suvannavejh tells investors in a research note. He believes efgartigimod has a "best-in-class profile" and could reach peak global risk-adjusted sales of EUR 1.6B. Further, Argenx has been advancing cusatuzumab, a novel anti-CD70 antibody for potential use in blood cancers, says the analyst. Suvannavejh also upgraded Orchard Therapeutics (ORTX) to Buy from Neutral and raised his price target for the shares to $21 from $18. The analyst projects $1.2B in peak global sales or Orchard's leading programs and sees "limited" clinical risk. With multiple sets of clinical data expected throughout 2019 on three late-stage candidates currently in registrational trials, anticipated news flow in 2019 could position shares of Orchard well for potential appreciation, Suvannavejh writes.

TODAY'S FREE FLY STORIES

CLR

Continental Resources

$46.94

1.8 (3.99%)

17:14
02/18/19
02/18
17:14
02/18/19
17:14
Earnings
Continental Resources reports Q4 adjusted 54c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Mar

SPN

Superior Energy

$4.43

0.165 (3.87%)

16:53
02/18/19
02/18
16:53
02/18/19
16:53
Earnings
Superior Energy reports Q4 EPS ($4.85), may not compare consensus (0.28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

MSG

Madison Square Garden

$291.37

0.85 (0.29%)

16:46
02/18/19
02/18
16:46
02/18/19
16:46
Periodicals
MSG denies Knicks sale talks after Bill Simmons claims otherwise »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

16:45
02/18/19
02/18
16:45
02/18/19
16:45
Hot Stocks
Windstream postpones release of Q4, FY18 financial results »

Windstream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UFPI

Universal Forest

$32.22

0.36 (1.13%)

16:43
02/18/19
02/18
16:43
02/18/19
16:43
Hot Stocks
Universal Forest signs agreement to acquire Wolverine Wood Products »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:36
02/18/19
02/18
16:36
02/18/19
16:36
Earnings
Breaking Earnings news story on Service Corp. »

Service Corp. sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:34
02/18/19
02/18
16:34
02/18/19
16:34
Earnings
Service Corp. reports Q4 adjusted EPS 54c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

APY

Apergy

$36.84

0.92 (2.56%)

16:27
02/18/19
02/18
16:27
02/18/19
16:27
Earnings
Apergy reports Q4 adjusted EPS 36c, consensus 33c »

Reports Q4 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NAVI

Navient

$11.75

0.12 (1.03%)

16:20
02/18/19
02/18
16:20
02/18/19
16:20
Hot Stocks
Navient rejects highly conditional unsolicited 'expression of interest' »

Navient announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$14.41

-0.005 (-0.03%)

16:15
02/18/19
02/18
16:15
02/18/19
16:15
Hot Stocks
24 SandBox Logistics patent claims invalidated »

Proppant Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 28

    May

JBHT

J.B. Hunt

$113.78

1.66 (1.48%)

16:12
02/18/19
02/18
16:12
02/18/19
16:12
Hot Stocks
J.B. Hunt completes acquisition of Cory 1st Choice Home Delivery »

J.B. Hunt announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 06

    Mar

CAT

Caterpillar

$136.21

3.575 (2.70%)

16:10
02/18/19
02/18
16:10
02/18/19
16:10
Hot Stocks
Caterpillar announces several officer moves »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

CUB

Cubic

$60.35

2.995 (5.22%)

16:07
02/18/19
02/18
16:07
02/18/19
16:07
Hot Stocks
Cubic announces semiannual dividend of 13.5c per share »

Cubic announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

HMC

Honda

$27.35

0.04 (0.15%)

13:11
02/18/19
02/18
13:11
02/18/19
13:11
Periodicals
Honda plan to close U.K. plant not due to Brexit, Reuters reports »

Honda plans to shut its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$27.35

0.04 (0.15%)

13:07
02/18/19
02/18
13:07
02/18/19
13:07
Periodicals
Honda to close U.K. car plant in 2022, Reuters reports »

Honda is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNMF

Lundin Mining

$0.00

(0.00%)

13:04
02/18/19
02/18
13:04
02/18/19
13:04
Downgrade
Lundin Mining rating change at Goldman Sachs »

Lundin Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVR

Chicago Rivet & Machine

$28.36

0.56 (2.01%)

12:38
02/18/19
02/18
12:38
02/18/19
12:38
Hot Stocks
Chicago Rivet & Machine announces increase in quarterly cash dividend to 22c »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

, XRX

Xerox

$30.46

0.63 (2.11%)

12:36
02/18/19
02/18
12:36
02/18/19
12:36
Hot Stocks
Quest Diagnostics names Gabrielle Wolfson senior VP, CIO »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

XRX

Xerox

$30.46

0.63 (2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRDX

Surmodics

$56.79

3.09 (5.75%)

12:29
02/18/19
02/18
12:29
02/18/19
12:29
Hot Stocks
Surmodics announces appointment of Timothy Arens as CFO »

Surmodics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

CUB

Cubic

$60.35

2.995 (5.22%)

, IBM

IBM

$138.05

1.55 (1.14%)

12:28
02/18/19
02/18
12:28
02/18/19
12:28
Hot Stocks
Cubic names IBM, Microsoft executive Kevin Eagan as Senior VP, Chief Digital »

Cubic (CUB) announced the…

CUB

Cubic

$60.35

2.995 (5.22%)

IBM

IBM

$138.05

1.55 (1.14%)

MSFT

Microsoft

$108.19

1.35 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

CGUSY

Casino Guichard Perrachon

$0.00

(0.00%)

11:50
02/18/19
02/18
11:50
02/18/19
11:50
Downgrade
Casino Guichard Perrachon rating change at Deutsche Bank »

Casino Guichard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$0.00

(0.00%)

11:46
02/18/19
02/18
11:46
02/18/19
11:46
Downgrade
Centrica rating change at Berenberg »

Centrica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/18/19
02/18
11:15
02/18/19
11:15
General news
FX Summary: AUD-JPY has been the biggest mover »

FX Summary: AUD-JPY has…

MSM

MSC Industrial

$86.24

0.81 (0.95%)

11:07
02/18/19
02/18
11:07
02/18/19
11:07
Hot Stocks
MSC Industrial reports patent issued for cost-savings documentation system »

As previously reported on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

08:35
02/18/19
02/18
08:35
02/18/19
08:35
General news
Oil Action: Front-month WTI crude futures are up 1.0% »

Oil Action: Front-month…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.